AIMD

HOUSTON, TX / ACCESS Newswire / May 13, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today announced financial results for the first quarter ended March 31, 2026 and provided a business update on recent execution progress for AI Nose across semiconductors and healthcare infrastructure applications . During the first quarter of 2026, Ainos continued executing its commercialization priorities for AI Nose across industrial infrastructure environments while continuing to expand its Smell ID datasets and refine its Smell Language Model ("SLM") through deployment and pilot activities. "Our first quarter progress reflects a continued transition from validation activities toward broader enterprise-level infrastructure deployment readiness," said Eddy Tsai, Chairman, President and CEO of Ainos. "We believe the operational milestones achieved during the quarter has strengthened the foundation for future scalable commercialization of Smell AI - powered by AI Nose." "In addition to our progress in semiconductor environments, we are expanding AI Nose deployment into healthcare infrastructure settings, including hospital utility systems, laboratory environments, HVAC-related monitoring, MRI-related environments, and critical infrastructure safety applications. We believe this represents an important long-term application category for AI-driven environmental intelligence, by enabling continuous monitoring, anomaly awareness, and operational stability for hospital operation," Mr. Tsai concluded. Christopher Lee, Chief Financial Officer of Ainos, added, "During the first quarter, we strengthened our balance sheet and liquidity position through the previously announced NT$90 million (approximately US$2.8 million) financing arrangement while maintaining operating discipline as we advanced commercialization activities. Reported operating expenses declined approximately 30% year-over-year to approximately US$2.28 million." "Revenue during the quarter reflected the Company's ongoing transition toward industrial and infrastructure-focused AI Nose deployments, which remain in earlier stages of commercialization and validation. We believe our current execution priorities will help support broader revenue generation opportunities in the second half of 2026," Mr. Lee added. First Quarter 2026 and Recent Operational Highlights Continued deployment activitie...

AI Nose drove 499% revenue growth in 2025, with gross margin turning positive to 82.9% 2025 partnerships now driving scaled AI Nose deployments in 2026, supported by disciplined financing HOUSTON, TX / ACCESS Newswire / March 30, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today reported financial results for the year ended December 31, 2025 and outlined commercialization momentum entering 2026. During 2025, Ainos expanded its industrial ecosystem of AI Nose platform across semiconductor, smart factory, robotics, and industrial AI environments, establishing the foundation for deployment-driven growth. AI Nose deployments combine hardware sensing with recurring software and data monetization through Smell IDand the Smell Language Model (SLM). "2025 marked our transition in expanding AI Nose's commercial focus from healthcare into industrial markets. Our focus in 2025 was building the platform and partnerships required for scale," said Eddy Tsai, Chairman and CEO of Ainos. "As we enter 2026, that groundwork is translating into operational momentum, with early AI Nose deployments underway, particularly in semiconductor environments. As deployments expand, AI Nose generates Smell ID data that continuously trains our SLM, reinforcing our long-term data advantage." "In 2025 we maintained a disciplined financial approach while supporting SmellTech platform's scale. Total revenue increased approximately 499% year over year, mainly reflecting progress in our AI Nose commercialization. Gross margin improved significantly to approximately 82.9% in 2025, compared to a gross loss in 2024. Total operating expenses, excluding share-based compensation, depreciation and amortization, decreased 9% year-over-year, reflecting operational discipline as we prepare for deployment-driven growth, while reported operating expense increased about 2%," Christopher Lee, CFO, commented. "Subsequent to year-end, we strengthened our financial position through a New Taiwan Dollar 90 million financing (approximately USD$2,820,000), providing additional liquidity to support ongoing operations and deployment execution. This capital enhances our flexibility as we scale AI Nose commercialization while maintaining a disciplined approach to capital allocation," Lee added. Semiconductor Deployment Scaling Gains Momentum in 2026 In 2026, Ainos has launched early-stage d...

Open-Label Study Demonstrates Durable Reduction in Oral Inflammation with Favorable Tolerability Profile at Interim Analysis HOUSTON, TEXAS / ACCESS Newswire / February 17, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a SmellTech platform company digitizing scent as a native data language for artificial intelligence, today announced interim results from its ongoing open-label, multi-dose clinical trial evaluating VELDONA, a low-dose oral interferon alpha formulation, for the treatment of Feline Chronic Gingivostomatitis (FCGS), a severe, chronic inflammatory oral disease in companion animals. The study is designed to enroll 12 client-owned cats diagnosed with FCGS across two dosing cohorts (6,000 IU and 12,000 IU administered orally three times per week for six weeks). The interim analysis includes the first six treated subjects. Enrollment remains ongoing. Interim Efficacy Results The primary disease activity assessment utilized the Stomatitis Disease Activity Index (SDAI; range 0-30), a composite score integrating: Veterinary assessment of oral inflammation Body weight changes Owner-reported activity and feeding behavior At Week 6: The majority of subjects demonstrated reductions in total SDAI scores. Directional improvement in overall disease activity was observed across the cohort. No clinically significant rebound was observed through Week 14 follow-up. Local oral inflammation scores demonstrated consistent and statistically significant improvement: 6 of 6 cats showed lower oral inflammation scores at Week 6 compared to baseline. Mean improvement reached approximately 38% at Week 6. 66.7% of subjects achieved ≥30% clinically meaningful improvement. Wilcoxon signed-rank testing demonstrated statistical significance (p < 0.05). At Week 14 follow-up, mean improvement in oral inflammation increased to approximately 45%, suggesting sustained benefit after completion of the six-week treatment course. Notably, one subject that did not undergo full-mouth dental extraction achieved measurable clinical improvement during interferon therapy, supporting a therapeutic effect independent of surgical recovery and consistent with an immunomodulatory mechanism. Ainos plans to continue enrollment toward the full 12-subject target and further evaluate dose-response relationships, durability of effect, and safety outcomes in the complete datas...

Relocation to sharpen operating efficiency and anchor Ainos in Texas' fast-growing technology ecosystem New subsidiary to accelerate smell language model development and extend AI Nose's data-driven platform strategy SAN DIEGO, CA / ACCESS Newswire / December 16, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) today announced that it will relocate its U.S. headquarters to Houston, Texas in early 2026 and has formed its wholly owned subsidiary, ScentAI Inc. ("ScentAI"), a pure AI software company created to advance development of its smell language model (SLM)-an emerging AI model that enables scent intelligence for machines by digitizing scent signals into Smell IDs. Ainos will relocate to Houston to strengthen operating efficiency and position its U.S. operations within one of the country's most dynamic technology and industrial innovation hubs. Houston's expanding ecosystem across advanced manufacturing, energy, healthcare, robotics, and AI directly aligns with Ainos' platform strategy and commercialization roadmap. "Ainos was incorporated in Texas, and relocating our U.S. headquarters to Houston in early 2026 marks both a strategic return and a forward-looking step," said Mr. Eddy Tsai, Chairman and CEO of Ainos, Inc. "This move improves operating efficiency, allows us to capitalize on Texas' rapidly growing technology ecosystem, and provides us with access to a deep and competitive talent pool as we accelerate AI Nose deployment and expand our ecosystem." Mr. Tsai added, "Over the past decade, the AI Nose platform, powered by SLM, has built a strong data moat, accumulating real-world scent data across medical, industrial, and environmental settings. Over the past year, we have translated that foundation into execution momentum across Asia, where AI Nose is expanding into broader industrial, semiconductor, automation, and robotics sectors, targeting large-scale deployment in 2026. Establishing Houston as our U.S. base enables us to extend that momentum back to the United States and deepen our global ecosystem." In parallel, Ainos formed ScentAI as a dedicated AI-driven software subsidiary focused on advancing the smell language model (SLM). ScentAI will operate as a pure software company, developing AI models that allow machines to understand, classify, and interpret scent as a structured data language - Smell ID. Ainos will co-locate ScentAI with its head...

Digital olfactory commercialization accelerates toward 2026 scale-up, as industrial partnerships expand to six and the IP moat strengthens. World's first patented commercial AI Nose device launched, advancing SmellTech-as-a-Service adoption. SAN DIEGO, CALIFORNIA / ACCESS Newswire / November 13, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a leader in AI-driven scent digitization, today announced its financial results for the third quarter ended September 30, 2025. Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, "Ainos continued to execute with focus as we build the foundation for the 2026 commercial scale-up of our core scent-digitization technology platform, AI Nose. This quarter, we further strengthened our market position by adding new strategic partners in the semiconductor and industrial edge AI sectors, expanding our network of major industrial collaborators to six and advancing the buildout of a comprehensive SmellTech ecosystem. Together, these collaborations extend AI Nose into high-value applications in semiconductors, industrial automation, and robotics-accelerating adoption through broader sales and service channels and validating digital olfaction as a transformative capability for intelligent sensing." "We are delivering on our commitments. AI Nose pilots are scaling rapidly, setting the stage for wider commercial rollouts in 2026. Market interest has also been reinforced by strong visibility at major industrial exhibitions, where Ainos showcased the world's first commercial AI olfactory system that transforms scent into a machine-readable data layer for industrial and healthcare applications." "AI is redefining the electronic-nose market by strengthening odor analysis and identification, underscoring the strategic soundness of our focus on AI-driven SmellTech. According to third-party research, the global electronic-nose market is projected to grow from approximately $45 billion in 2025 to more than $130 billion by 2034, representing a 12.7% compound annual growth rate. Asia-Pacific is expected to lead the next growth wave-precisely where Ainos is building scale. Our proprietary Smell Language Model (SLM) and over a decade of data experience give us a powerful competitive edge. As a U.S.-incorporated company, I believe our strong momentum in Asia is strat...

1H 2025 Kicks Off AI Nose's Growing Commercial Momentum with First Senior Care Revenue and New Strategic Partnerships AI Nose 90-Day Roadmap to Power 2H 2025, with First Multi-Year $2.1M Order and Traction Across Robotics, Semiconductors, and Smart Manufacturing SAN DIEGO, CA / ACCESS Newswire / August 13, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a leader in AI-driven scent digitization, today announced its financial results for the second quarter ended June 30, 2025. Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, "We're thrilled that our proprietary AI-powered scent digitization platform, AI Nose, has entered the commercial execution phase. The first half of 2025 marked a strategic inflection point as we successfully transitioned from R&D to revenue-generating deployment in Japan. With new real-world pilot programs underway and a clear path to scaled adoption, we've set the stage for the second half with accelerating momentum and expanding commercial traction." "The increasing integration of AI across multiple industries strongly reinforces our strategic focus on AI-driven SmellTech. According to third-party research, demand for electronic nose is growing in healthcare, environmental monitoring, and industrial automation-key sectors where AI Nose is already gaining momentum. Through strategic partnerships, we're expanding AI Nose into a multi-industry deployment ecosystem. I believe our expanding ecosystem both broadens our scent database and enhances our smell language models ("SLMs"), paving the way for a SmellTech-as-a-Service subscription model. Designed to generate scalable, recurring revenue, this model supports high-value applications such as scent analytics, predictive monitoring, and digital Smell ID profiling-extending value well beyond hardware sales." "I'm very excited about AI Nose's increasing momentum in the industrial market. Earlier this month, we secured our first three-year subscription order valued at $2.1 million for the first deployment of AI Nose in a semiconductor manufacturing setting. It is also our second commercial success, following first revenue in the senior care sector during 1Q 2025. Following the software-hardware integration of AI Nose into our first robotic partner's robots, we are launching pilot deployments of the world's first...

Early results show steroid-free remission, opening pathway into $13B global pet dental health market VELDONA delivers consistent anti-inflammatory effects, strengthening Ainos' positioning in companion animal immunotherapy SAN DIEGO, CALIFORNIA / ACCESS Newswire / May 19, 2025 / Ainos, Inc. (Nasdaq:AIMD)(Nasdaq:AIMDW) ("Ainos"), a pioneer of low-dose oral interferon therapeutics, today announced compelling interim results from its ongoing veterinary clinical trial using low-dose interferon VELDONA for treating Feline Chronic Gingivostomatitis ("FCGS"), a chronic inflammatory conditions in cats. The interim results demonstrate meaningful improvements in inflammation and a consistent reduction in steroid dependency, indicating strong commercial and scientific potential for a novel class of immunotherapy in companion animals. The randomized, controlled trial aims to enroll 30 cats, divided into high- and low-dose treatment groups, to assess pre- and post-treatment inflammation scores, corticosteroid usage, and safety. The focus is on chronic inflammatory diseases such as feline gingivostomatitis-an area where effective long-term treatments remain limited and largely reliant on steroids. To date, three cats have completed treatment, with a fourth currently in progress. All cases have shown clear clinical improvements and strong tolerability: Case 1 (5-year-old cat, severe oral inflammation): Inflammation score reduced from 19 to 17 (10.5% improvement) Previous treatment with a French high-dose injectable interferon treatment was ineffective Steroid dose successfully reduced from 0.8mg/kg/day to 0.5mg/kg/day with stable condition Case 2 (14-year-old cat, chronic inflammation): Score reduced from 16 to 12.3 (23.1% improvement) Steroid therapy was fully discontinued two months after treatment; condition remains stable Case 3 (index case): Score reduced from 9 to 5 (44.4% improvement) Steroids discontinued post-treatment; no relapse observed No significant side effects were observed in any case. The results also suggest a steroid-sparing effect, which is critical for improving long-term outcomes in aging or chronically ill pets. Dr. Albert Yu, Technical Director of Pharmaceuticals at Ainos, commented: "We are witnessing a potential paradigm shift in treating chronic inflammatory diseases in companion animals. Our interferon therapy not only shows efficacy in reducin...

Q1 revenues increased 412% year over year, driven by AI Nose products Delivers strong turnaround from gross loss to gross profit in Q1 AI Nose gains traction beyond healthcare with strategic partnerships in robotics and semiconductor sectors VELDONA&reg; program advances with TFDA and IRB Approvals for two clinical trials in Taiwan SAN DIEGO, CALIFORNIA / ACCESS Newswire / May 12, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company") today announced its financial results for the first quarter ended March 31, 2025. Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, "Q1 2025 represents a significant step forward in advancing our long-term strategy to build a differentiated healthcare and technology company powered by scent digitization, AI-enhanced diagnostics and innovative therapeutics. Revenues increased 412% year over year, primarily driven by sales of AI Nose products for elderly care under the Nisshinbo Micro Devices Inc. ("NISD") co-development project. This performance is a testament to the growing commercial viability of our proprietary AI Nose technology in healthcare." "While our AI Nose technology has a deep root in healthcare use-case, we are expanding the application scope into the robotics and industrial sectors. We've made rapid progress in establishing strategic partnerships, including collaborations with a leading Japanese service robot developer to embed AI Nose into robots, and with the world's largest semiconductor packaging and testing provider to deploy AI Nose in semiconductor manufacturing environments. " "Rising AI integration across industries validates our strategic direction. The global electronic nose market is projected to grow from $29.8 billion in 2025 to $76.5 billion by 2032. Demand is rising across healthcare, environmental, and industrial sectors-precisely where our AI Nose is gaining traction. In the industrial space, industrial robot installment grew 10% year over year to 4.28 million units in 2024, with rising integration of AI and sensors-an environment where we believe AI Nose can play a critical role in adding olfactory intelligence to automation systems. In healthcare, our scent-based applications for early disease detection align with the AI healthcare market, expected to surpass $180 billion by 2030." "The U.S. Treasury Secretary recently...